ArticleFrontiers in immunology2026
Inhaled bovine lactoferrin modulates the p47phox-MPO-NETosis axis in acute lung injury: implications for bioengineered nanomedicine in respiratory infections.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial immune profiling of local tissues and its correlation with peripheral blood cytokines in lung squamous cell carcinoma patients with immune-related pneumonitis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Excessive oxidative burst and dysregulated neutrophil extracellular trap (NET) formation contribute to tissue damage in acute lung injury (ALI) and are largely driven by the combined actions of NADPH oxidase 2 (NOX2) and myeloperoxidase (MPO). While lactoferrin (LTF) is a known multifunctional immunomodulatory glycoprotein, its precise role in modulating the NOX2-MPO-NETosis axis in ALI remains undefined. Methods: We employed a time-course model of lipopolysaccharide (LPS)-induced ALI in C57BL/6N mice, combined with quantitative label-free lung proteomics and downstream bioinformatic analyses to map dynamic molecular changes. At the inflammatory peak, aerosolized bovine lactoferrin (bLF) was administered in vivo, and histological lung injury, pulmonary inflammatory cytokine levels, neutrophil infiltration, and markers related to the NOX2-MPO-NETosis axis were evaluated. Results: LPS induced typical ALI pathology that peaked between days 1 and 3 (D1-D3). Proteomic and network analyses consistently highlighted NET formation as a centrally enriched early KEGG pathway and identified LTF as a key protein-protein interaction hub closely connected to p47phox (encoded by Ncf1) and MPO. Evaluation of aerosolized bLF demonstrated significant mitigation of ALI pathology, reducing lung injury, pro-inflammatory cytokines, and neutrophil recruitment. Mechanistically, bLF suppressed NETosis by reducing p47phox and MPO expression and, crucially, diminished p47phox phosphorylation in vivo, consistent with reduced NOX2 activation. Discussion: These findings identify LTF as a critical dynamic regulator of the p47phox-MPO-NETosis axis in LPS-induced ALI. They also highlight bLF as a promising candidate for further translational evaluation and support the rationale for developing bioengineered, lactoferrin-based nanomedicines aimed at modulating innate immunity and mitigating neutrophil-driven lung injury in respiratory infectious diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.